1. Home
  2. FOLD vs CSQ Comparison

FOLD vs CSQ Comparison

Compare FOLD & CSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amicus Therapeutics Inc.

FOLD

Amicus Therapeutics Inc.

HOLD

Current Price

$14.19

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Logo Calamos Strategic Total Return

CSQ

Calamos Strategic Total Return

HOLD

Current Price

$19.19

Market Cap

3.1B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
FOLD
CSQ
Founded
2002
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
3.1B
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
FOLD
CSQ
Price
$14.19
$19.19
Analyst Decision
Buy
Analyst Count
8
0
Target Price
$29.79
N/A
AVG Volume (30 Days)
14.8M
220.3K
Earning Date
11-04-2025
01-01-0001
Dividend Yield
N/A
7.53%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$598,704,000.00
N/A
Revenue This Year
$21.49
N/A
Revenue Next Year
$18.25
N/A
P/E Ratio
N/A
N/A
Revenue Growth
21.28
N/A
52 Week Low
$5.51
$12.50
52 Week High
$14.36
$16.45

Technical Indicators

Market Signals
Indicator
FOLD
CSQ
Relative Strength Index (RSI) 91.10 56.05
Support Level $10.64 $18.67
Resistance Level $11.14 $19.44
Average True Range (ATR) 0.36 0.21
MACD 0.28 -0.01
Stochastic Oscillator 96.46 67.53

Price Performance

Historical Comparison
FOLD
CSQ

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

About CSQ Calamos Strategic Total Return

Calamos Strategic Total Return Fund is a diversified, closed-end management investment company. The fund's objective is to provide total return through a combination of capital appreciation and current income. Its investment portfolio comprises equities, convertible securities, and high-yield corporate bonds.

Share on Social Networks: